Introduction
Neuromyelitis optica spectrum disorder (NMOSD) is a rare autoimmune disease of the central nervous system that predominately affects the optic nerves and spinal cord. Serum antibodies against the astrocytic aquaporin-4 antigen (AQP4-abs) are considered important factors of pathogenesis. Acute treatment of relapses includes high-dose intravenous methylprednisolone (IVMP), IV immunoglobulins (IVIG), and plasma exchange. For long-term immunotherapy and relapse prophylaxis oral corticosteroids and immunosuppressive drugs, such as azathioprine or mycophenolate mofetil have been proposed, yet, B cell depletion with the chimeric anti-CD20-antibody rituximab is widely considered treatment of choice. However, up to 30% of patients suffer from clinical relapses in spite of complete B cell depletion as measured by flow cytometric analysis. [1] [2] [3] For those patients the treatment with the interleukin-(IL)-6-receptor blocking antibody tocilizumab has been proposed as a viable alternative. 4 We report two female adolescents who were treated with tocilizumab after relapsing under B cell depletion.
Case 1
A previously healthy 17-year-old girl presented with hypesthesia of both hands, proprioception deficits in both legs, and urinary retention. Spinal magnetic resonance imaging (MRI) showed longitudinally extensive transverse myelitis (LETM) from C1 to the conus; cranial MRI revealed no abnormalities (►Fig. 1). Cerebrospinal fluid (CSF) studies showed a mild pleocytosis with slightly increased protein,
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Case 2
A previously healthy 17-year-old girl presented with acute onset of paresthesia of both legs that increased with exercise. Three days later she described an additional severe pruritus on the back. Initial MRI showed LETM, but no intracranial abnormalities (►Fig. 1). CSF analysis revealed a mild pleocytosis with negative oligoclonal bands. In serum, AQP4-abs (1:10,240) were detected using live cell-based assays. Treatment with IVMP (30 mg/kg; 3 days) was initiated which led to resolution of pruritus and paresthesia. In the following days, the patient started suffering from anesthesia of the abdomen and the front of both thighs that resolved without treatment within 3 weeks. One month later the patient relapsed with paresthesia of chest and both legs as well as cramps of the right leg that increased on movement (EDSS 2.0). No visual deficits were noted. Treatment with IVMP, PLEX (8x), oral prednisolone tapering, and rituximab (375 mg/m 2 BSA, 4 weeks interval) was started which led to improvement of symptoms. One month later the patient relapsed with paresthesia and pruritus of the left chest and shoulder while under complete B cell depletion as measured by flow cytometric methods. Spinal MRI showed significant disease progression with multiple new intramedullary lesions (►Figs. 1 and 2). After additional PLEX (4x), therapy with tocilizumab (8 mg/kg, monthly) was started which led to clinical stabilization. Follow-up MRI revealed residual signal changes, but no new lesions (►Figs. 1 and 2). At the latest clinical follow-up, the patient had remained relapsefree for 18 months after initiation of tocilizumab (EDSS 1.0). The AQP4-ab titers had not changed significantly.
Discussion
We report two female adolescents with AQP4-abs positive NMOSD who clinically stabilized after switching treatment from rituximab to monthly administrations of tocilizumab. Despite the efficacy of rituximab, up to 30% of patients suffer from clinical relapses in spite of complete B cell depletion.
1-3
Pathophysiologically, CD20-depletion resistant plasmablasts have been proposed as origin of AQP4-abs in rituximab therapy resistant cases. Chihara et al identified CD19 int CD27 high CD38 high CD18 À plasmablasts in NMOSD that secrete AQP4-abs in an IL-6 dependent manner. 5 In addition, they reported increased levels of IL-6 in NMOSD relapses. Therefore, targeted therapy with the IL-6-blocking antibody tocilizumab has been suggested as an alternative to standard treatment.
5
The escalation of therapy in case of rituximab therapy refractory NMOSD is a matter of debate. Our two patients were switched to tocilizumab 1 and 3 months, respectively, after initiation of rituximab treatment and confirmed B cell depletion. Some authors have described a time lag between B-cell depletion and clinical stabilization of NMOSD patients treated with rituximab. In such cases, a bridging therapy with, for example, low-dose corticosteroids has been proposed. 6 Another option would be to switch to one of the widely used steroid-sparing drugs mycophenolate mofetil or azathioprine. A multicenter study comparing treatment efficacy of rituximab, azathioprine, and mycophenolate mofetil in NMOSD showed the highest reduction of relapse rate in patients treated with rituximab. 7 In case of treatment failure switching to either azathioprine or mycophenolate mofetil led to a significant reduction in relapse rate. 7 Mycophenolate mofetil and azathioprine are known to show a delay in clinical efficacy of several months. Due to the high clinical and paraclinical disease activity in both patients, the risk of further disabling relapses was considered high. Therefore, we decided to switch to tozilizumab. Clinical data on tocilizumab treatment in NMOSD is sparse and has only been reported in adults in small case series and case reports. A current clinical trial (NCT02028884), including patients from 12 years of age aims at evaluating the efficacy and safety of satralizumab (SA237), another IL-6-blocking antibody, as add-on in the treatment of NMOSD. In terms of pediatric populations, only a single case of a 14-year-old male patient suffering from Sjögren's syndrome and NMOSD has been reported who became relapse-free after switching to tocilizumab.
8
While previous reports in adults have shown mild recurrence in some patients, no relapses were seen in our two cases. This might be due to adaptation of administration frequency and dosing to recommendations published in a recent report 9 (4 weekly infusions and 8 mg/kg, respectively). However, one of our patients showed slowly progressive decrease in visual acuity during treatment without clinical signs of acute attack or further deterioration of OCT.
In terms of safety, no severe adverse effects or increased frequency of infections have been noted in our patients. We conclude that early switching to tocilizumab might pose a viable treatment option in B cell-depletion resistant pediatric NMOSD. Larger studies are necessary to reliably evaluate efficacy and safety and define the patient groups who will profit most from this treatment.
Patient Consent
Written informed consent for patient information and MR images to be published was provided by the patients. The study was approved by the institutional review board (Ethikkomission der Medizinischen Universität Wien, No. EK1123_2015).
Study Funding
This study was supported in part by the grant "Jubiläums-fonds der Österreichischen Nationalbank, Project 16919" to R.H.
